Skip to main content
Clinical Trials/NCT05220202
NCT05220202
Recruiting
Not Applicable

MOTIVATE to Improve Outcomes for Older Veterans With Musculoskeletal Pain and Depression

VA Office of Research and Development4 sites in 1 country264 target enrollmentSeptember 20, 2023

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Chronic Back Pain
Sponsor
VA Office of Research and Development
Enrollment
264
Locations
4
Primary Endpoint
Primary Outcome: Pain interference
Status
Recruiting
Last Updated
8 months ago

Overview

Brief Summary

The proposed study seeks to evaluate effectiveness, implementation processes, and cost of MOTIVATE among older Veterans with chronic musculoskeletal (MSK) pain and comorbid depressive symptoms.

Detailed Description

Investigators will conduct a randomized controlled trial (RCT) at two large VA facilities, to establish the effectiveness and scalability of MOTIVATE, a remotely delivered behavioral intervention for older Veterans with comorbid musculoskeletal (MSK) pain and depressive symptoms. The central hypothesis is that MOTIVATE will improve important patient-centered outcomes among older Veterans with co-occurring MSK pain and depressive symptoms.

Registry
clinicaltrials.gov
Start Date
September 20, 2023
End Date
December 1, 2026
Last Updated
8 months ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Aged 60 and older
  • English- speaking
  • Self-reported MSK pain (include cLBP +/- radiating symptoms, OA, fibromyalgia) on most days for the past 3 months that interferes with daily activities
  • Pain intensity that is 4+/10 on the numerical pain rating scale
  • Pain interference threshold 5+ on PEG-3
  • Depressive symptoms, 10+ on PHQ-9
  • Capable of participating in home-based activity
  • Interested in participating in a non-pharmacologic program

Exclusion Criteria

  • Aged 59 or less
  • No telephone
  • Not English speaking
  • Unwilling to be randomized to either study arm
  • Not interested in participating in a non-pharmacologic program
  • Self-reported uncorrected hearing and visual impairments precluding ability to participate in telephone sessions or read pedometer screen
  • Significant (moderate or severe) cognitive impairment (3+ errors) on six-item screening exam
  • Self-reported dependence on wheelchair, bed-bound, or severe balance impairment or severe OA\* (resulting in inability to participate in physical activity intervention)
  • Illness requiring hospitalization within the last 3 months that interferes with a home-based physical activity intervention (e.g., fall, gout attack, stroke, heart attack, heart failure, surgery for blocked arteries)
  • Suicidal intent (see suicide screening protocol), uncontrolled psychotic disorder or psychiatric hospitalization within 1 year, or enrolled in active substance use program (confirmed with scripted protocol over telephone)

Outcomes

Primary Outcomes

Primary Outcome: Pain interference

Time Frame: 3 months post baseline or completion of MOTIVATE

Pain interference will be assessed using the interference subscale of the Brief Pain Inventory (BPI) score at 3 months post-baseline or completion of MOTIVATE. Patient-reported pain-related interference (0-10 scale, with higher values indicating more pain) has been shown to be sensitive to change and to have good reliability. A mean between-group difference of 1-point in the primary outcome (change of BPI interference score from baseline to 3 months) is considered a clinically meaningful difference.

Secondary Outcomes

  • Pain Catastrophizing(Baseline, Mid (~5 weeks), End (~3 months) and 6 months)
  • Quality of Life using PROMIS Global Health Scale(Baseline, Mid (~5 weeks), End (~3 months) and 6 months)
  • Patient Global Impression of change scale(Baseline, Mid (~5 weeks), End (~3 months) and 6 months)
  • Anxiety(Baseline, Mid (~5 weeks), End (~3 months) and 6 months)
  • Depressive symptoms, PHQ-9(Baseline, Mid (~5 weeks), End (~3 months) and 6 months)
  • Pain Behavior(Baseline, Mid (~5 weeks), End (~3 months) and 6 months)
  • Arthritis self-efficacy(Baseline, Mid (~5 weeks), End (~3 months) and 6 months)
  • Therapeutic Alliance(Mid (~5 weeks), End (~3 months))
  • Social Functioning(Baseline, Mid (~5 weeks), End (~3 months) and 6 months)
  • Sleep Disturbance(Baseline, Mid (~5 weeks), End (~3 months) and 6 months)
  • Insomnia Severity Index(Baseline, Mid (~5 weeks), End (~3 months) and 6 months)
  • Psychological resilience(Baseline, Mid (~5 weeks), End (~3 months) and 6 months)
  • FRAIL scale(Baseline, Mid (~5 weeks), End (~3 months) and 6 months)

Study Sites (4)

Loading locations...

Similar Trials